SCHEMBL784775

SCHEMBL784775

CN(C(=O)c1ccc2c(c1)[C@H](NC(=O)C1CCc3ccccc31)CC2)C1CCN(c2ccncc2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 2/20 0.39
CCR5 P51681 1/20 0.38
AURKA O14965 1/20 0.38
CTSS P25774 1/20 0.38
MAPT P10636 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KCNQ2 O43526 1/20 0.37
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
MCHR1 Q99705 1/20 0.36
TAOK1 Q7L7X3 1/20 0.36
TAOK3 Q9H2K8 1/20 0.36
F10 P00742 1/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
ROCK2 O75116 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL785421 0.96 CTSS (0.42) P2RX7CTSSMAPTSMN1; SMN2TAOK1
SCHEMBL784378 0.96 CTSS (0.42) P2RX7CTSSMAPTSMN1; SMN2TAOK1
SCHEMBL803442 0.96 CTSS (0.42) P2RX7CTSSMAPTSMN1; SMN2TAOK1
SCHEMBL785390 0.90 P2RX7 (0.38) P2RX7CCR5AURKACTSSJAK2
SCHEMBL785875 0.89 MCHR1 (0.39) CCR5CTSSJAK2JAK1MCHR1
SCHEMBL784410 0.87 POLB (0.41) CCR5CTSSMCHR1F10POLB
SCHEMBL785446 0.87 CTSS (0.52) CCR5AURKACTSSPDE4APDE4B
SCHEMBL786234 0.87 CCR5 (0.40) CCR5CTSSJAK2JAK1MCHR1
SCHEMBL784304 0.86 POLB (0.42) CCR5CTSSMCHR1F10POLB
SCHEMBL784555 0.86 NAMPT (0.38) CCR5JAK2JAK1MCHR1F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US claimed
CN-103097354-A Substituted benzamide compounds GRUENENTHAL CHEMIE 2013-05-08 CN claimed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US claimed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
US-8680159-B2 Bradykinin 1 receptor modulating compounds GRUENENTHAL GMBH (DE) 2014-03-25 US disclosed
CN-103097354-A Substituted benzamide compounds GRUENENTHAL CHEMIE 2013-05-08 CN disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed
US-20120071461-A1 Substituted Benzamide Compounds GRUENENTHAL GMBH (DE) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071461-A1 Substituted Benzamide Compounds BDKRB1, BDKRB2, HRH2 P2RX7 140/4885CCR5 460/4885AURKA 3163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.